Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 292

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 292
---
 Proceeds from bank loan                                                                                               -                    5,248                        -  
  Proceeds from SPAC merger and PIPE financing, net of transaction cost                                            93,543                        -                        -  
  Proceeds from exercise of Warrants                                                                                3,335                        -                        -  
  Proceeds from exercise of options                                                                                    27                       49                       25  
  Net cash provided by financing activities                                                                        96,905                    5,297                       25  
  Effect of exchange rate changes on cash and cash equivalents                                                      ( 258                     ( 50                       57  
  (Decrease) increase in cash and cash equivalents                                                               ( 17,168                    5,971                    1,067  
  Cash and cash equivalents at the beginning of the year                                                           23,854                    6,686                   12,657  
  Cash and cash equivalents at the end of the year                                 $                                6,686      $            12,657      $            13,724  
  Supplemental disclosure                                                                                                                                                    
  Income taxes paid                                                                $                                    8      $                16      $                 5  
  Interest received                                                                $                                  237      $             6,160      $             4,424  
  Interest paid                                                                    $                                    -      $                52      $               321  
  Supplemental disclosure                                                                                                                                                    
  Operating lease liabilities arising from obtaining right of use assets           $                                    -      $             3,304      $                35  

The accompanying notes are an integral part of
the consolidated financial statements.

F-7

ALPHA TAU MEDICAL LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 1:- GENERAL

  Company description:  
 ────────────────────────

Alpha Tau Medical
Ltd. (“the Company”) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization
of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November
2015 and began its operations in January 2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera
Medical Ltd., (“ Althera”), developed in 2003 at Tel Aviv University.

In August 2017 the
Company established a fully owned subsidiary in the United States